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Summary For the first time in a clinical study oral Ifosfamide was used: 65 elderly or unfit patients with
small cell lung cancer (SCLC) were treated as outpatients with fractionated oral Ifosfamide and Etoposide. Forty
patients (62%) had extensive stage (ED) disease. The median age of the patients was 66 years. In the 60
patients evaluable for response the objective response rate was 90% with a complete response (CR) rate of
32% and a partial response (PR) rate of 58%. The overall median survival of all 65 patients was 11 months
(13 months for LD, 9.5 months for ED). In those patients with LD achieving a CR or a PR radiotherapy was
given to the mediastinum. No prophylactic cranial irradiation was given. There was a rapid improvement in
the responding patients' performance status and symptoms generally with the first treatment cycle. Overall
haematological toxicity was mild, with intravenous antibiotics only being required in 4% of the courses and
with only one treatment-related death from septicaemia. A higher than expected rate of CNS toxicity was
seen (30%). This was generally mild and always fully reversible and consisted mainly of forgetfulness,
occasionally hallucinations, nightmares and somnolence. In only one case did encephalopathy necessitate early
termination of treatment. This raises the question of whether Ifosfamide metabolism differs quantitatively or
qualitatively when given by the oral route as opposed to the usual intravenous route. We conclude that this
simple outpatient based treatment gives a high response rate with rapid improvement in symptoms.
During the past decade various aggressive combination
chemotherapy and combined modality treatment regimens
have been used for patients with small cell lung cancer
(SCLC). Despite high objective response rates (70-90%)
the overall long-term survival (2 years) is less than 20%
(Morstyn et al., 1984; Joss et al., 1987). No major advance
has been achieved since and it has been shown that prog-
nostic factors are probably more important in determining
survival than the treatment modality (Souhami et al., 1985;
Cerny et al., 1987a; Klastersky, 1988). The main aim of
treatment in the group of elderly and poor prognosis
patients is currently to relieve symptoms and improve the
quality of life.
Our own experience with the two drug combination
Ifosfamide and Etoposide given intravenously gave results
similar to the more aggressive three and four drug combi-
nations (Thatcher et al., 1987). In addition we have pre-
viously shown that the bioavailability of oral Ifosfamide is
close to 100% (Cerny et al., 1986). Therefore we decided to
combine oral Ifosfamide with oral Etoposide; the later drug
is widely used in the treatment of SCLC because of its
known single agent activity in this disease (Cavalli et al.,
1978; Comis, 1986). Ifosfamide was chosen because of its
high single agent activity in SCLC (Brade et al., 1985). In
addition both drugs are thought to be non-cross-resistant as
multi-drug resistance and topoisomerase II are involved in
Etoposide resistance (Graydon-Harker et al., 1986; McVie,
1988) while glutathione transferase is involved in alkylating
drug resistance (Teicher et al., 1986; McGown et al., 1986).
Both drugs were given in a fractionated regimen as both
drugs appear to have a higher therapeutic index when used
in this manner (Cavalli et al., 1978; Klein et al., 1984).
Fractionation of the Ifosfamide dosage results in increased
alkylating activity in the serum (Cerny et al., 1987b). The
bioavailability of oral Etoposide is 50% in the low dose
range (<200mgdose-1) but is more unpredictable at higher
doses (Slevin et al., 1986). We therefore decided on an oral
Etoposide dosage of 100mg per day for 8 days in conjunc-
tion with oral Ifosfamide. This regimen was designed as an
effective outpatient treatment of attractive simplicity without
the need for costly hospitalisation.
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Patients and methods
Patients
Sixty-five patients with cytologically or histologically proven
diagnosis of SCLC were entered in this prospective study
from September 85 to June 86. All patients with CNS
metastases at time of diagnosis were excluded as were
patients with elevated serum creatinine. Thirty-six patients
>65 years (17 LD, 19 ED) who were either in the bad or
intermediate category as defined by the Manchester scoring
system (12 patients) or were medically unfit for intensive
chemotherapy were enrolled into this study. In addition 29
patients aged less than 65 years (8 LD, 21 ED) were treated
with this regimen irrespective of their Manchester score (15
good, 8 intermediate and 6 bad prognostic group) because
they were medically unfit for intensive chemotherapy. Medi-
cally unfit patients were those who had the following
conditions: recent myocardial infarction, diabetes mellitus or
cerebrovascular disease. Prognosis was defined by a recently
published scoring system in which there were no 2-year
survivors found in the bad prognostic group (Table I).
The median age of all patients was 66 years, ranging from
39 to 81 years with 36 patients (55%) of > 65 years; 17
patients were female and 48 male. Forty (62%) patients had
ED stage including 22 patients with liver metastases and the
remaining 25 patients had a limited disease stage (Table II).
Staging procedures included clinical examination, a com-
plete haematological and biochemical profile, biplane chest-
X-ray and a bone marrow biopsy and trephine. Liver
ultrasound, liver scintigraphy, abdominal CT scan or bone
scintigraphy were performed where indicated by clinical,
Table I Prognostic score (Manchester score)
+1 if LDH >450U1-' (upper normal limit)
+ 1 if extensive disease
+1 if sodium <132mmoll-
+1 if Karnofsky performance score <60
+1 if alkaline phosphatase >165U1- (1.5-fold upper limit)
+1 if bicarbonate <24mmoll-
Total number=score
Group 1 (good prognostic group) =score 0 and 1
Group 2 (intermediate) score 2 and 3
Group 3 (bad prognostic group) =score 4+
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Table II Patient characteristics
Total number
Sex female 17
male 48
Age median 66
range 39-
>65 years 36
Stage limited disease 25
extensive disease 40
liver metastases 22
bone marrow involv. 4
bone metastases 19
other 5
Initial Karnofsky score
K70
>70
65 (10oo0%)
years
-81 years
(55%)
(38%)
(620%)
31 (48%)
34 (52%)
Table III Response to treatment with oral ifosfamide and etoposide
Stage OR CR PR SD PD
Limited disease
(n=21) 20 12 8 0 1
Extensive disease
(n=39) 34 7 27 2 3
All (n-60) 54 (90%) 19 (32%) 35 (58%) 2 4
OR, overall response; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease.
Table IV Median Karnofsky score during chemotherapy
Course (n=65) 2(n=65) 3(n =62) 4(n=56) 5(n=48) 6(n =38)
Median 60 70 80 80 90 90
Range 40-60 40-90 70-90 60-90 60-90 30-90
biochemical or radiological abnormalities. Response was
assessed according to the WHO standard criteria (WHO,
1979).
Treatment protocol
Ifosfamide was given orally as a fixed dose of 2g each
morning on days 1 to 3 with Etoposide 100mg given once a
day for eight consecutive days. Both drugs were given 30
min before breakfast. Mesna was given orally with fruit juice
or cola at time 0, 4h and 8 h at a dosage of 400mg each,
and patients were told to maintain a fluid intake of at least
1.51 per day (Brock et al., 1982). Courses were repeated
every 3 weeks. In responding patients a total of six courses
were given. Complete responders or those with a good
partial response who had initially limited disease were addi-
tionally treated with mediastinal irradiation 3-4 weeks after
the last course of chemotherapy. No prophylactic CNS
irradiation was given. A less demanding single exposure of
thoracic irradiation (1250cGy) using a rotation technique
was employed in patients with a CR.
Treatment was stopped if there was progressive disease or
unacceptable toxicity. In relapsing patients no second line
chemotherapy was given but symptomatic treatment includ-
ing radiotherapy was administered.
Nadir and pretreatment blood counts were routinely per-
formed. Chest radiography, assessment of the patients'
symptoms, Karnofsky score and MRC respiratory score
were performed at each clinical visit.
Chemotherapy courses were deferred by 1 week if the
pretreatment leukocyte counts were <3.5 x 1091-1 or the
platelets <100 x 1091-1. In symptomatic anaemic patients
blood transfusions were given and infective episodes were
immediately treated with broad spectrum antibiotics.
Response and toxicity was reported according to WHO
criteria (WHO, 1979). CNS toxicity was assessed by asking
the patients and their relatives at each visit whether they had
experienced nightmares, hallucinations, forgetfulness, con-
fusion or excessive somnolence. After completion of all
therapy patients were routinely reassessed every 3 months, or
earlier if they showed symptoms of disease.
Results
Sixty of the 65 patients were evaluable for response. The
non-evaluable patients were excluded for response for the
following reasons: three had prior surgery, one early death
from septicaemia and one patient had severe encophalopathy
due to Ifosfamide during the first course preventing her from
further treatment with Ifosfamide. However, none were
excluded from the survival analysis as shown in Figures 1
and 2.
The treatment results are shown in Table III. The overall
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Figure 1 Survival of all 65 patients with SCLC treated with oral
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Table V Toxicity of treatment during 321 courses (%)
WHO I/II WHO III/IV
Haematological toxicity Hb-nadir 79(25) 7(2)
Lc-nadir 76(24) 18(5)
Pl-nadir 15(4) 2(0.5)
Infective episodes total 20(6)
treated with oral antibiotics 6
treated with iv antibiotics 14
septicaemic early death 1
Delayed courses 23(7)
CNS-toxicity grade 1 and 2 65(25)
grade 3 14(4)
grade 4 3(1)
Nausea and vomiting grade 1 146(45)
grade 2 31(10)
grade 3 6(2)
grade 4 0
Grading of toxicity according to WHO Handbook (WHO, 1979).
response was 90% (54/60) with a complete remission rate of
32% (19/60). The majority of patients (86%, 52/60) res-
ponded during the first two cycles and therefore sympto-
matic relief was rapid. This has been shown by a highly
significant increase in Karnofsky as compared with pretreat-
ment values (Table IV, both P<0.0001 Friedman Test).
The median survival time for all 65 patients was 11
months, being 9.5 months for patients with ED and 13
months for LD patients. For complete responders the
median survival was 13 months, for partial responders 10.5
months and for non-responders 3 months. The median
survival for the 12 patients (20%) with LD who achieved a
CR has not yet been reached. The overall 2-year survival is
12% (22% for LD and 6% for ED). The survival curves are
shown in Figure 1 for all patients and separately according
to stage (Figure 2).
Toxicity (Table V) was generally mild. Of the 60 evaluable
patients, 38 (63%) received all six courses. Twenty-three
(7%) of a total of 321 courses had to be delayed by one
week because of myelosuppression. There were 20 (3%)
infective episodes requiring intravenous antibiotics in six
patients and oral antibiotics in 14 patients. Five of these
episodes were in LD and 15 in ED patients, which is
significant (P<0.01). Early death was seen in one patient
due to septicaemia during the first course of treatment.
Alopecia was total in all patients receiving more than two
courses of chemotherapy.
Mild reversible CNS toxicity occurred in 25% of courses
and was severe in 5% of courses. Somnolence was the major
problem but forgetfulness, nightmares and hallucinations
also occurred in some patients. In only one female patient
did severe encophalopathy (fully reversible) necessitate early
termination of treatment. Generally CNS toxicity occurred
on the second or third day of treatment, but in some
patients it was apparent as early as a few hours following
the first dose of Ifosfamide. CNS toxicity was more common
in ED stage patients. It did not appear to be due to Mesna
as one patient developed encophalopathy who did not take
the oral Mesna. Slight nausea was common and often
patients attributed this to the oral Mesna. No urotoxicity
has been observed.
Discussion
For most patients with SCLC simple outpatient based
treatment modalities with a high response rate are needed.
The main aim is palliation of the symptomatic disease.
For the first time oral Ifosfamide was used in a clinical
study. It was combined with the widely used Etoposide for
treatment of elderly or medically unfit SCLC patients. The
outpatient based regimen described above obtained a high
response rate (90%) with rapid improvement in patients'
symptoms. The toxicity was low, with one septicaemic death
and with only 14 (4%) infective episodes requiring intra-
venous antibiotics. Nausea and vomiting were mild and
manageable but some patients could not tolerate the oral
Mesna. A capsular formulation may help circumvent the bad
taste of Mesna.
The rate of encephalopathy was higher in this study (30%)
than generally quoted elsewhere (Brade et al., 1985) but in
only one patient was this severe enough to warrant stopping
treatment. The mechanism of Ifosfamide encephalopathy is
ill understood. However, it did not appear to be due to
Mesna because it also occurred in one patient who did not
take this uroprotector. It would seem that oral adminis-
tration results in a higher level of CNS side-effects and this
would suggest that there is a first pass effect. Recently it has
been shown that oral administration results in a higher level
of Ifosfamide metabolites in the urine after the oral as
compared to intravenous route (Roberts et al., 1989).
The response rates and median survival achieved in this
study were comparable to those achieved with more intensive
combination regimens (Joss et al., 1987). However, it must
be realised that the patient population studied was very
heterogeneous with regard to prognostic factors in that
patients from poor, intermediate and also good prognostic
categories were included in this trial.
We feel that this simple and well tolerated outpatient
based oral treatment regimen is as effective as more toxic
and costly standard treatment modalities. Simplicity and low
risk of severe toxicity may help acceptance of palliative
chemotherapy in patients with SCLC.
T. Cerny was a recipient of an EORTC Research Fellowship.
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